Get In Touch
Have any questions or comments about the content you see on this page?
February 20, 2019
Alnylam has been named a Fast Company World's 50 Most Innovative Company for 2019, number 3 in the Biotech category and number 32 overall. We are incredibly honored to have been recognized by Fast Company for our innovation in developing RNAi (RNA interference) therapeutics as a new class of medicines.
From Fast Company:
"Alnylam became the first company to bring an RNA interference (RNAi) treatment to market, winning FDA approval for its drug Onpattro in August 2018. The culmination of a 16-year quest to realize the promise of Nobel-winning research, Onpattro treats..." You can read more from Fast Company here.
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.Proceed to Site